Research programme: diclofenac foam - Foamix

Drug Profile

Research programme: diclofenac foam - Foamix

Alternative Names: Diclofenac 1% foam - Foamix; Diclofenac 3% foam - Foamix; DicloFoam 1%; DicloFoam 3%

Latest Information Update: 02 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Foamix
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Actinic keratosis; Musculoskeletal pain; Osteoarthritis

Most Recent Events

  • 27 Jan 2011 Preclinical development is ongoing in Israel
  • 12 Sep 2005 Diclofenac foam is available for licensing (
  • 12 Sep 2005 Preclinical trials in Actinic keratosis in Israel (Topical, 3% foam)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top